Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAWNA-A: Dalpiciclib in Adjuvant HR+/HER2- Breast Cancer
NCT04842617Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative) comparing Dalpiciclib + ET with Placebo + ET (2 arms). Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Apr 2021; status: active, not recruiting.
02
Drugs
dalpiciclib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT04842617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04842617.